1. Home
  2. ALLO vs MLAB Comparison

ALLO vs MLAB Comparison

Compare ALLO & MLAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ALLO
  • MLAB
  • Stock Information
  • Founded
  • ALLO 2017
  • MLAB 1982
  • Country
  • ALLO United States
  • MLAB United States
  • Employees
  • ALLO N/A
  • MLAB N/A
  • Industry
  • ALLO Biotechnology: Biological Products (No Diagnostic Substances)
  • MLAB Industrial Machinery/Components
  • Sector
  • ALLO Health Care
  • MLAB Industrials
  • Exchange
  • ALLO Nasdaq
  • MLAB Nasdaq
  • Market Cap
  • ALLO 545.8M
  • MLAB 682.5M
  • IPO Year
  • ALLO 2018
  • MLAB N/A
  • Fundamental
  • Price
  • ALLO $2.69
  • MLAB $133.06
  • Analyst Decision
  • ALLO Buy
  • MLAB Hold
  • Analyst Count
  • ALLO 12
  • MLAB 2
  • Target Price
  • ALLO $10.26
  • MLAB $140.00
  • AVG Volume (30 Days)
  • ALLO 1.7M
  • MLAB 26.4K
  • Earning Date
  • ALLO 10-31-2024
  • MLAB 11-04-2024
  • Dividend Yield
  • ALLO N/A
  • MLAB 0.48%
  • EPS Growth
  • ALLO N/A
  • MLAB N/A
  • EPS
  • ALLO N/A
  • MLAB N/A
  • Revenue
  • ALLO $65,000.00
  • MLAB $223,712,000.00
  • Revenue This Year
  • ALLO N/A
  • MLAB $11.31
  • Revenue Next Year
  • ALLO $6,292.80
  • MLAB $5.12
  • P/E Ratio
  • ALLO N/A
  • MLAB N/A
  • Revenue Growth
  • ALLO 6.56
  • MLAB 2.02
  • 52 Week Low
  • ALLO $2.01
  • MLAB $82.86
  • 52 Week High
  • ALLO $5.78
  • MLAB $141.17
  • Technical
  • Relative Strength Index (RSI)
  • ALLO 49.96
  • MLAB 58.26
  • Support Level
  • ALLO $2.55
  • MLAB $120.37
  • Resistance Level
  • ALLO $2.87
  • MLAB $135.46
  • Average True Range (ATR)
  • ALLO 0.17
  • MLAB 3.61
  • MACD
  • ALLO 0.00
  • MLAB 0.36
  • Stochastic Oscillator
  • ALLO 46.67
  • MLAB 84.10

About ALLO Allogene Therapeutics Inc.

Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases. Their pipeline includes off-the-shelf T-cell candidates designed to target cancer cells or autoreactive cells in autoimmune disorders. Notably, their allogeneic approach, derived from healthy donors, allows for broader patient eligibility and scalability. With a vision to redefine CAR T therapy, the company concentrates on core programs targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue, primarily generated from collaborations and licensing agreements, supports their research and development efforts.

About MLAB Mesa Laboratories Inc.

Mesa Laboratories Inc manufactures life sciences tools and critical quality control products. It operates in 4 divisions: Sterilization and Disinfection Control, which manufactures and sells biological, chemical, and cleaning indicators used to assess the effectiveness of sterilization, decontamination, disinfection, and cleaning processes. Clinical Genomics division develops, manufactures, and sells highly sensitive, low-cost, high-throughput genetic analysis tools and related consumables. The Biopharmaceutical Development division develops, manufactures, and sells automated systems for protein analysis (immunoassays) and peptide synthesis solutions. The Calibration Solutions division develops, manufactures, sells, and services quality control products.

Share on Social Networks: